摘要:目的: 在風濕性心臟病患者瓣膜置換術中,評價羅庫溴銨在麻醉誘導期間對患者心肌氧供和氧耗平衡的影響。 方法 :選擇86例在中低溫體循環下行瓣膜置換術的患者,采用隨機雙盲法分配成羅庫溴銨組(n=42例)和維庫溴銨組(n=41例)。給予咪唑安定(005~01 mg/kg)及芬太尼(10~15μg/kg)及等效劑量的羅庫溴銨06 mg/kg或維庫溴銨01 mg/kg(Org. Comp)進行麻醉誘導。監測麻醉誘導前至插管后10分鐘(1次/1分)期間兩組患者心肌氧供和氧耗的變化。 結果 :與基礎值相比,羅庫溴銨組患者在插管后5分鐘期間心率增加了174%~135%,動脈收縮壓增加了1694%~143%,平均動脈壓增加了151%~132%。同期心率收縮壓乘積增加了2267%~1396% (〖WTBX〗P lt;005)。心率和動脈血壓在插管后1~7分鐘期間明顯高于同期的維庫溴銨組患者(〖WTBX〗P lt;005)。 結論 :在ASA ⅢⅣ級、心功ⅡⅢ級風心病瓣膜病變患者進行瓣膜置換術中, 06 mg/kg羅庫溴銨有潛在增加患者心肌耗氧量的作用。Abstract: Objective: To evaluate the effects of rocuronium on myocardial oxygen supplydemand in patients with rheumatic heart disease (RHD) during induction. Methods : 86 patients of either sex (ASA status ⅢⅣ; New York Heart Association classes ⅡⅢ) scheduled for valve replacement surgery were included in this randomized clinical trial (RCT). SwanGanz catheter was placed via right internal jugular vein before the induction of anaesthesia. Anaesthesia was induced with midazolam 00501mg.kg-1 and fentanyl 1015 μg·kg-1. The patients were randomized to receive either rocuronium 06 mg·kg-1 (group R, 〖WTBX〗n= 42) or vecuronium 01 mg·kg-1 (group V, 〖WTBX〗n= 41) to facilitate tracheal intubation when bispectral index (BIS) value dropped to 60 All data were recorded at the time before anaesthesia (Tb), loss of consciousness (Ts), administration of muscle relaxant (Tm), 1 min after administration of muscle relaxant (T1), when trainoffour stimulation (TOF) reached 0 (T2) and 1,2,3,4,5,7,10 min after tracheal intubation (T39).〖WTHZ〗Results : Heart rate (HR) increased by 174%135%, systemic arterial systolic pressure (SAP) increased by 1694%143%, mean arterial systolic pressure (MAP) increased by 151%132% and product of heart rate and arterial systolic pressure(RPP) increased 2267%1396% respectively during 5 minutes after intubation as compared with baseline in group R, which were significantly higher than those in group V during 5 minutes after intubation (〖WTBX〗P lt;005). Conclusion : An intubation dose of rocuronium should be used cautiously in patients with rheumatic heart disease (ASA status ⅢⅣ; NYHA classes IIⅢ).